Salesforce is down roughly 23% from its 52-week high and rallying hard into its most consequential earnings report in years. The stock closed around $207.53 on August 21. Q2 FY2027 results land after the bell on August 26. Four days.
The question is not whether Salesforce can grow. It is whether the one number that matters, the cRPO growth rate, will confirm that the $1.2 billion Agentforce machine is pulling forward real multi-year contract commitments, or whether the headline ARR is still mostly early-pilot noise.
Why This Stock Now
Salesforce is the Dow’s worst-performing component in 2026. It hit a low of $146.32 in late June. It has since recovered more than 40% off that floor. That recovery is not sentiment-driven, though sentiment has improved. It is contract-driven. Between July 24 and early August, Salesforce closed two of the largest government AI deals in software history: a $1.6 billion, three-year Agentic Enterprise License Agreement with the U.S. Department of Veterans Affairs, and a $5.6 billion, 10-year Army contract through Computable Insights.
Those wins force a specific question: are they one-offs, or do they signal that Agentforce is becoming genuine enterprise infrastructure? August 26 begins to answer that.
The Business
Salesforce is the world’s largest customer relationship management platform. In fiscal year 2026, Salesforce’s revenue was $41.5 billion, an increase of 10% year-over-year. That growth rate is fine but not exceptional. What changed the conversation is Agentforce, the company’s autonomous AI agent platform.
Salesforce provides customer relationship management technology across the United States, Europe, and Asia Pacific, and offers Agentforce, which enables customers to build, deploy, and manage enterprise-grade, autonomous AI agents at scale, enabling humans and agents to work together. The pitch is specific: instead of buying seat licenses for human workers, enterprises buy consumption-based agent licenses that complete tasks without human input.
Investors got scared of a specific question: what happens to seat-based software pricing when AI agents replace human workers? The company built its business selling software seats, one license per human. If AI agents replace some of those humans, the traditional seat model shrinks. That fear drove CRM from above $269 to below $147 in six months. What the fear missed is that Salesforce is not the victim of the agentic shift. It is attempting to be the operator of it.
Why Wall Street Is Paying Attention
In Q1 FY2027, Agentforce annual recurring revenue crossed $1.2 billion, up 205% year over year, making it the fastest-scaling AI product line any enterprise SaaS company has reported in 2026. That is not a small number. Combined with Data 360 and Informatica Cloud, Agentforce and Data 360 ARR reached $3.4 billion, with Agentforce ARR growing over 200% year-over-year and significant expansion from existing customers.
The land-and-expand signal is important. More than 50% of Agentforce and Data 360 bookings during Q1 came from existing customers expanding deployments. Existing-customer expansion at higher consumption tiers is the textbook signal of product-market fit in a consumption-based SaaS pricing model, the exact opposite of pilot churn.
Usage is scaling fast. The platform processed 28.6 trillion tokens in Q1, up 152% sequentially from Q4 FY2026, with 3.8 billion Agentic Work Units created, an increase of 111% sequentially. Slack’s AWUs grew 350% quarter-over-quarter, and Slack contributed to nearly half of million-dollar wins, up 80% year-over-year.
Government contracts are the newest validation layer. The U.S. Department of Veterans Affairs awarded Salesforce a $1.6 billion, three-year, Agentic Enterprise License Agreement. Embedding autonomous AI agents directly into live workflows will automate benefits verification, streamline patient triage, and slash appointment scheduling times from 28 days to minutes. That is a concrete, measurable, public outcome Salesforce can use in every future government AI pitch.
Multiple banks have raised their targets in the past two weeks. JPMorgan started coverage with an Overweight and a $250 target on August 13. BMO Capital lifted its target to $230 on August 20. UBS raised to $210. According to 51 analysts, the average rating for CRM stock is Buy, with a 12-month price target of $243.08.
What’s Driving the Opportunity
Q1 FY2027 revenue of $11.13 billion beat Wall Street’s consensus estimate of $11.05 billion. Non-GAAP earnings per share came in at $3.88, beating the analyst expectation of $3.13 by about 24%. The CRM giant also posted a non-GAAP operating margin of 34.8%, up 250 basis points year-over-year, alongside a GAAP operating margin of 21.1%, up 130 basis points. That margin expansion matters. A 34.8% non-GAAP operating margin on a software company with triple-digit AI ARR growth is not what bears expected when they pushed the stock below $150.
The buyback is another force. Salesforce launched a $25 billion accelerated share repurchase program, funded through new debt, as part of its larger $50 billion buyback authorization approved in February 2026. Under this program, Salesforce immediately received 103 million shares. In total, the company returned $27.5 billion to shareholders during the quarter. That is an unusual amount of capital return for a company growing AI ARR at 200%+. Management is not hedging.
FY27 revenue guidance was raised to $45.9 billion to $46.2 billion. The $63 billion FY30 target signals management confidence. Whether those targets require Agentforce to compound at current rates or can be reached on legacy CRM growth alone is the structural question going into August 26.
On the technical side, during the past year, Salesforce stock moved between $146.32 at its lowest and $269.11 at its peak. At $207, the stock sits in the middle of that range. The 52-week low is 30% below current levels. The 52-week high implies another 30% of upside. The risk-reward is roughly symmetrical from here unless Thursday’s cRPO data breaks the tie.
What Could Go Wrong
Three risks are worth taking seriously.
The first is the USDA counter-signal. On August 11, The Information reported that the U.S. Department of Agriculture, which spends about $3 billion annually on IT and uses Salesforce for pretty much everything, is tapping C3 AI specifically to reduce its Salesforce footprint. The USDA report matters precisely because Salesforce’s 2026 bull thesis has leaned on federal validation. A federal agency actively reversing course doesn’t erase the VA and Army commitments, but it complicates the government signals universal confidence argument.
The second is the balance sheet. Noncurrent debt jumped from $10.4 billion to $39.3 billion, and shareholders’ equity fell 43.57% year-over-year. The $25 billion buyback was funded with debt, not free cash flow. That works if Agentforce monetization accelerates. It becomes a constraint if growth disappoints.
The third is competitive pressure. Microsoft, ServiceNow, and Oracle are sharpening competing agentic offerings. Analysts at KeyBanc cited CIO survey feedback in which Salesforce was described as a standout for negative reasons, with customer conversations on Agentforce failing to match the headline ARR momentum. There is a gap between what Salesforce is reporting and what some buyers are experiencing on the ground. That gap closes or widens on August 26.
Finally, the guidance issue. Until August 26 produces a specific number, cRPO growth rate and Q3 guidance, that confirms Salesforce’s promised second-half revenue reacceleration, the stock has signaled it will treat every analyst upgrade as temporary noise. That pattern has held all summer. JPMorgan’s $250 Overweight on August 13 sent the stock to $201.37 before it reversed to $196.21 the same week. Analyst upgrades are not enough.
The Bottom Line
The case for Salesforce right now is not a valuation argument. At roughly 13x forward earnings with 77% gross margins and double-digit revenue growth, CRM trades at an unusually cheap valuation even before Agentforce gains full traction. That cheapness has existed for months without moving the stock. What changes Thursday is whether cRPO growth, measured in constant currency, shows that the Army and VA deals plus Agentforce enterprise expansion are building a backlog that organic revenue can grow into.
Salesforce is scheduled to report Q2 FY2027 results on August 26, 2026. The analyst consensus across roughly 53 covering firms projects adjusted EPS of $3.27 to $3.28 and revenue near $11.3 billion, representing year-over-year growth of roughly 12.4% in earnings and 10.4% in revenue. Beat those numbers with cRPO acceleration and Q3 guidance at or above $11.5 billion, and the case for a sustained recovery becomes structural rather than speculative.
Miss on cRPO while the USDA counter-signal festers, and the June low of $146 is a real conversation again.
For investors who can hold through that binary, Simply Wall St’s valuation model estimates the intrinsic value at $362 per share. The 51-analyst consensus sits at $243. Both figures imply meaningful upside from $207 if the Agentforce monetization thesis proves out over the next two quarters. The thesis is specific. The catalyst is four days away. That combination is rare.